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Significance of this study
What is already known about this subject?
 ► People of South Asian descent are at a twofold to 
fourfold increased risk of type 2 diabetes (T2D) com-
pared with people of European descent.
What are the new findings?
 ► Concentrations of metabolites associated with T2D 
differ between South Asians and Europeans.
 ► In both Dutch and South- Asian Surinamese, high-
er plasma concentrations of certain acylcarnitines, 
glycine, glutamine and lactosylceramides decreased 
T2D risk, while higher plasma concentrations of (di-
hydro)ceramides and most amino acids increased 
T2D risk.
 ► The ethnic differences in amino acid and lactosylce-
ramide concentrations could potentially contribute to 
the higher T2D risk among South- Asian Surinamese 
compared with Dutch; however, ceramide profiles 
are more beneficial among South- Asian Surinamese.
How might these results change the focus of 
research or clinical practice?
 ► The results may be used as starting point to unravel 
ethnic differences in T2D risk by identifying underly-
ing metabolic disturbances.
 ► Plasma amino acid and sphingolipid concentrations 
may be used as markers to identify people at risk 
for T2D.
AbStrAct
Introduction People of South Asian origin are at high risk 
of type 2 diabetes (T2D), but the underpinning mechanisms 
are not fully understood. We determined ethnic 
differences in acylcarnitine, amino acid and sphingolipid 
concentrations and determined the associations with T2D.
Research design and methods Associations between 
these metabolites and incident T2D among Dutch and 
South- Asian Surinamese were determined in participants 
from the Healthy Life in an Urban Setting (HELIUS) study 
(Amsterdam, the Netherlands) using Prentice- weighted 
Cox regression. The HELIUS study includes 95 incident T2D 
cases and a representative subcohort of 700 people from 
a cohort of 5977 participants with a mean follow- up of 4 
years.
Results Concentrations of acylcarnitines were 
comparable between both ethnic groups. Amino acid 
and lactosylceramide concentrations were higher 
among South- Asian Surinamese than Dutch (eg, 
isoleucine 65.7 (SD 16.3) vs 60.7 (SD 15.6) µmol/L). 
Ceramide concentrations were lower among South- Asian 
Surinamese than Dutch (eg, Cer d18:1 8.48 (SD 2.04) vs 
9.08 (SD 2.29) µmol/L). Metabolic dysregulation preceded 
T2D without evidence for a multiplicative interaction 
by ethnicity. Most amino acids and (dihydro)ceramides 
were associated with increased risk (eg, Cer d18:1 HR 
2.38, 95% CI 1.81 to 3.12) while acylcarnitines, glycine, 
glutamine and lactosylceramides were associated with 
decreased risk for T2D (eg, LacCer d18:2 HR 0.56, 95% CI 
0.42 to 0.77).
Conclusions Overall, these data suggest that the 
disturbances underlying amino acid and sphingolipid 
metabolism may be predictive of T2D risk in populations 
of both South Asian and European background. These 
observations may be used as starting point to unravel the 
underlying metabolic disturbances.
InTRoduCTIon
More than 425 million people are affected 
by type 2 diabetes (T2D) worldwide, and this 
number is expected to grow to 629 million by 
2045.1 The incidence of T2D is two to four 
times higher among South Asian compared 
with people of European descent.2 3 The 
etiological mechanisms behind the ethnic 
differences in T2D risk are not fully under-
stood. One potential contributor to these 
differences is lipid overload, which can lead 
to increased incomplete fatty acid oxidation, 
mitochondrial stress,4 5 and also to ectopic 
fat accumulation causing an increased use 
of non- oxidative pathways.6 These processes 
can be assessed by measuring circulating 
concentrations of branched- chain amino 
acids (BCAA) and acylcarnitines, which both 
serve as markers of mitochondrial stress,4 5 
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and circulating ceramides which may signify the use of 
non- oxidative pathways.6 Evidence exists that some sphin-
golipids, acylcarnitines, and BCAA and aromatic amino 
acids are associated with T2D.7–9 However, for other 
amino acids and many types of sphingolipids, there is 
very limited evidence of an association with T2D. Further-
more, it is unclear whether ethnic differences in these 
metabolite concentrations potentially contribute to the 
higher risk of T2D in South Asian compared with Euro-
pean populations. Therefore, it is necessary to determine 
the metabolite concentrations and identify the associa-
tions with T2D.
There is some limited evidence that both plasma 
concentrations of amino acids and acylcarnitines affect 
the risk of T2D,5 10 11 and that the strengths of these asso-
ciations differ between ethnic groups.5 12 To add to the 
limited evidence in base, we therefore aimed to investi-
gate the potential contribution of amino acids, acylcarni-
tines and sphingolipids to the high risk for T2D observed 
among South Asians. To do this, we used data from the 
Healthy Life in an Urban Setting (HELIUS; Amsterdam, 
the Netherlands). The results of our study will contribute 
to insights in mechanisms that are potentially important 
in the pathophysiology of T2D in diverse populations. 
Furthermore, it may add to efforts to identify persons 
who are at increased risk to develop T2D in these groups.
This study had three specific objectives. First, to quan-
tify baseline acylcarnitine, amino acid and sphingolipid 
plasma concentrations among Dutch and South- Asian 
Surinamese; second, to quantify the association between 
metabolites (acylcarnitines, amino acids and sphin-
golipids) and incident T2D; and third, to determine 
whether the strengths of associations are similar in Dutch 
and South- Asian Surinamese. Previous work has shown 
that, although absolute risks between people living in 
various countries may differ, relative differences in cardio-
vascular disease risk factors between ethnic groups are 
similar to other European countries, suggesting that our 
results are generalizable to other European countries.13
ReseaRCH desIgn and meTHods
Population
We used baseline data from the HELIUS study, which 
were collected between 2011 and 2015. HELIUS is a 
multiethnic cohort study among six ethnic groups living 
in Amsterdam. A detailed description of the design is 
available elsewhere.14 15 In brief, we randomly sampled 
participants from the municipal register, stratified by 
ethnicity. Questionnaires, physical examinations, and 
biological samples were obtained.15
A case–cohort design was used to increase efficiency.16 
Use of a case–cohort design can provide unbiased esti-
mates, without losing much precision compared with 
analyzing the full cohort.16 For this study, a random 
sample of 350 participants of Dutch and 350 participants 
of South- Asian Surinamese ethnicity was selected as the 
subcohort (control group). We focused on South- Asian 
Surinamese because we aimed to unravel the potential 
underlying causes for the high risk of T2D of South Asian 
origin populations compared with European origin 
populations. The Dutch participants were included as 
reference populations, since this ethnic group is the host 
population and at particular low risk for T2D.2 3 Acyl-
carnitines, amino acid and sphingolipid concentrations 
were determined for this subcohort, and for all partici-
pants who developed T2D (cases; figure 1).
measurements
Incident T2D cases were identified through record 
linkage with two healthcare registrations (online supple-
mentary material S1). We first linked HELIUS data by 
Citizen Service number to the Achmea Health Database 
with registrations from 1 January 2010 until 30 April 2016. 
Second, HELIUS data were linked to Vektis with probabi-
listic linkage based on data of birth, sex and postal code, 
with registrations from 1 January 2011 until 31 December 
2017. We defined incident T2D as a registration of one of 
the considered codes in either one of the databases, and 
not having T2D at baseline based on self- report, medica-
tion use, glucose or HbA1c levels. Follow- up duration was 
determined from inclusion date within HELIUS until the 
moment of data linkage, or the year that a participant 
developed T2D.
Ethnicity was defined by the individual’s country of 
birth combined with the parental countries of birth. 
Dutch ethnicity was assigned to participants born in the 
Netherlands, with both parents born in the Netherlands. 
South- Asian Surinamese ethnicity was assigned to partic-
ipants born in Suriname with at least one parent born in 
Suriname (first generation) or born in the Netherlands 
with both parents born in Suriname (second generation) 
combined with self- reported South Asian ethnic origin.15
Information on pack- years of smoking and physical 
activity was determined from the questionnaire. The 
number of pack- years was calculated by multiplying the 
number of packs (containing 20 cigarettes) smoked a 
day by the number of years. Smoking cigars and pipe 
tobacco was also included by calculating the equivalent 
rates of tobacco. The physical activity score was derived 
by the Short Questionnaire to Assess Health (SQUASH) 
enhancing physical activity, which includes questions on 
activities at work and school, leisure time, household 
activities, commuting activities and other daily activities 
and the intensity at which the activity was executed.17 
Results of the SQUASH enhancing physical activity 
were converted to minutes per week and multiplied by 
the metabolic equivalent (MET) intensity score. Body 
mass index (BMI) was determined by dividing measured 
body weight (kg) by height squared (m2). Weight and 
height were measured in barefoot subjects wearing light 
clothes only. Waist circumference was measured using a 
tape measure at the level mid- way between the lowest rib 
margin and the iliac crest. All anthropometric measures 
were taken in duplicate and the mean was used in the anal-
yses. If the discrepancy between the duplicate measures 
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Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of the inclusion of participants. A random 
sample of 350 participants per ethnic group was taken from the eligible population and included as the subcohort for whom 
metabolites were measured. In addition, metabolites were measured for all incident T2D cases. *A total of 95 cases developed 
T2D of which nine were in the subcohort. HELIUS, Healthy Life in an Urban Setting; T2D, type 2 diabetes.
differed more than 0.5 cm for height, more than 0.5 kg 
for weight or more than 1 cm for waist circumference, a 
third measurement was taken. The two measures which 
were most similar were used to calculate the mean.
Laboratory methods
Blood was collected after a fasting period of at least 
10 hours. Acylcarnitines and amino acids were determined 
in plasma by tandem- mass spectrometry as described 
previously.18 19 (Glyco)sphingolipids were determined 
using the following chemicals and reagents: sphingosine 
(d18:1), sphinganine (d18:0), 1- deoxysphinganine 
(m18:0), glucosylsphingosine (d18:1), lactosylsphin-
gosine (d18:1), and d5- glucosylsphingosine (d18:1) 
were from Avanti Polar Lipids and all organic solvents 
were from Biosolve (liquid chromatography- tandem 
mass spectrometry (LC- MS/MS) quality). Formic acid, 
butanol, and hydrochloric acid were obtained from 
Merck and globotriaosylsphingosine (d18:1), sodium 
hydroxide, and ammonium formate were from Sigma. 
Samples were prepared for analysis by extraction of 
(glyco)sphingolipids from plasma with chloroform 
and methanol. In short, 50 µL plasma was pipetted in a 
2 mL tube and 400 µL methanol and 200 µL chloroform 
were added. Extract was transferred to a 2 mL tube and 
separation of phases was induced by addition of 310 µL 
water. The lower phase was transferred to a Pyrex tube 
and the upper phase was washed with chloroform. Next, 
combined lower phases, containing (glyco)sphingolipids, 
were dried under a stream of nitrogen and the residue 
was dissolved in 500 µL 0.1 M sodium hydroxide in meth-
anol. Samples were subjected to microwave- assisted deac-
ylation and neutralized by addition of 1 M hydrochloric 
acid in methanol. Internal standard (d5- glucosylsphin-
gosine (d18:1)) was added to each sample followed by 
evaporation of methanol (N2, 40°C). Thereafter, samples 
were subjected to extraction with butanol:water (1:1, v/v). 
After drying the butanol phase, samples were dissolved in 
120 µL methanol and analyzed by LC- MS/MS. For that 
lyso(glyco)sphingolipids were separated by reversed- 
phase ultraperformance liquid chromatography (UPLC) 
using an Acquity I- Class UPLC with ethylene bridged 
hybrid C18 column, 2.1×50 mm with 1.7 µm particle size 
(Waters) and detected by electron spray ionization in 
positive mode and MS/MS instrument (Xevo TQ MS, 
Waters) in multiple reaction monitoring mode (online 
supplementary material S2).20 Levels of (glyco)sphin-
golipids were calculated using calibration lines within 
the appropriate concentration range, according to the 
internal standard ratio method.
statistical analyses
All analyses were conducted in RStudio V.0.99.903.21 
Metabolites with more than 5% of the data below the 
detection limit were excluded from further analyses as 
imputation may lead to inaccuracies.22 For other metab-
olites with measurements below the detection limit, 
concentrations of half the detection limit were imputed. 
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Table 1 Baseline characteristics in the subcohort* representative of the entire study population
Total subcohort 
(n=677)
Dutch subcohort
(n=334)
SA subcohort
(n=343)
Mean age (years) 45.0 (13.4) 46.0 (13.8) 44.0 (12.9)
% male (n) 46.7 (316) 49.4 (165) 44.0 (151)
Median pack- years of smoking 0.1 (0.0; 6.5) 1.2 (0.0; 10.0) 0.0 (0.0; 2.8)
Mean physical activity (MET/week) 2781 (1578) 2812 (1312) 2751 (1802)
Mean BMI (kg/m2) 25.1 (4.1) 24.4 (3.8) 25.7 (4.4)
Mean waist circumference (cm) 89.4 (12.3) 88.9 (12.2) 90.0 (12.3)
Socioeconomic status (%)
  Never been to school/elementary schooling only 7.4 (50) 4.2 (14) 10.5 (36)
  Lower vocational schooling or lower secondary 
schooling
21.8 (148) 10.8 (36) 32.7 (112)
  Intermediate vocational schooling or intermediate/
higher secondary schooling
26.1 (177) 21.9 (73) 30.3 (104)
  Higher vocational schooling or university 44.6 (302) 63.2 (211) 26.5 (91)
*Baseline characteristics of the subcohort are shown. The subcohort represents the full cohort as it is a random sample of the full cohort.
BMI, body mass index; MET, metabolic equivalent; SA, South- Asian Surinamese.
Finally, outliers for glycine (n=1), serine (n=1) and aspar-
agine (n=1) were set to the median concentration.
We first examined baseline characteristics and quanti-
fied metabolite concentrations in the subcohort, as the 
subcohort represented the entire population. We calcu-
lated means and SD for continuous normally distributed 
variables, medians and IQRs for continuous non- normally 
distributed variables and numbers of observations and 
percentages for categorical variables.
Second, we inspected if it was realistic to assume that 
the metabolites were normally distributed by plotting 
histograms and checking skewness and kurtosis. Since 
some metabolites followed a highly skewed distribution 
metabolites were log10 transformed and z- score stan-
dardized before further analysis; after transformation, all 
metabolites followed a normal distribution. Second, we 
used a summary score of the metabolites conducting a 
principal component analysis (PCA). We used the subco-
hort to construct the PCA and determined individual 
scores of cases with these factor loadings. We quantified 
the association between metabolites and incident T2D by 
weighted Cox proportional hazards regression models 
using the Prentice method to account for the case–cohort 
design. HRs for the association between metabolites and 
incident T2D were reported. Furthermore, to determine 
whether the strengths of associations are similar in Dutch 
and South- Asian Surinamese we checked the interaction 
between metabolites and ethnicity with incident T2D as 
the outcome. The interaction between sex and metabo-
lites was checked as well, but since none was observed we 
did not stratify our analyses by sex.
The models were adjusted for the confounders sex, 
age, smoking, physical activity, BMI and waist circum-
ference, and where relevant ethnicity. This was in accor-
dance with our conceptual model, published at  dagitty. 
net/ mrZnVAV. As a sensitivity analysis we additionally 
adjusted for socioeconomic status.
P values <0.05 were regarded as statistically significant. 
To avoid type 1 errors we characterized analyses with 
the principal components (PCs) as the main outcomes, 
and considered individual metabolites as secondary 
outcomes. Glutamate and glutamine, and asparagine and 
aspartate can convert into each other in the samples. We 
therefore also examined these metabolites combined. We 
adjusted analyses with individual metabolites for multiple 
testing by Holm adjustment.
ResuLTs
Baseline characteristics and metabolite concentrations
The mean age in the subcohort was 45.0 (SD 13.4) years 
old, with Dutch participants somewhat older than the 
participants of South- Asian Surinamese origin (figure 1 
and table 1). The random subcohort consisted of more 
women than men (53.3%), especially among South- Asian 
Surinamese (56.0%). Median pack- years of smoking was 
0.1 (IQR 0.0; 6.5), mainly due to very low prevalence of 
smoking among South- Asian Surinamese participants. 
Mean physical activity level was 2781 (SD 1578) MET/
week, with the Dutch being somewhat more active than 
South- Asian Surinamese. Mean BMI of the subcohort 
was 25.1 (SD 4.1) kg/m2, and mean waist circumference 
was 89.4 (SD 12.3) cm. These measures of adiposity were 
somewhat higher among South- Asian Surinamese than 
among the Dutch. Most participants (44.6%) were highly 
educated, while 7.4% of the participants had never been 
to school or only had elementary schooling. The Dutch 
were more highly educated than South- Asian Surinamese.
Baseline metabolite concentrations differed by 
ethnicity (figure 2; online supplementary material S3). 
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Figure 3 Associations between (A) acylcarnitines, (B) amino 
acids, and (C) sphingolipids and type 2 diabetes incidence. 
HRs and 95% CIs are shown. The model was adjusted for 
ethnicity, age, sex, smoking, physical activity, body mass 
index (BMI) and waist circumference.
Concentrations of most acylcarnitines were comparable 
between both ethnic groups. However, concentrations 
of carnitines C10:1, C14:2 and C18:2 were higher among 
South- Asian Surinamese, while concentrations of C6:DC 
and C18:0 were lower than in the Dutch. Larger ethnic 
differences were observed for amino acids. In particular, 
leucine, isoleucine, phenylalanine, tyrosine, alanine, 
methionine, glutamate and arginine were higher among 
South- Asian Surinamese than among Dutch participants. 
In addition, glycine was lower among South- Asian Suri-
namese in the subcohort. Most sphingolipid concen-
trations were either higher (the glucosylceramides, 
lactosylceramides and ceramides d16:1, d17:1, d18:1 and 
d20:1) among Dutch than South- Asian Surinamese or 
were comparable (globotriaosylceramides and ceramide 
d18:2) between both ethnic groups, except for deoxycer-
amide m18:0 which was lower among Dutch than South- 
Asian Surinamese.
Principal component analysis
The Kaiser- Meyer- Olkin measure of sampling adequacy 
was 0.91, with all scores above 0.50 (range, 0.61–0.98). 
Moreover, the Bartlett test of sphericity showed the 
correlation between metabolites was sufficiently large to 
perform a PCA (p<0.001; online supplementary material 
S4). The scree plot (online supplementary material S5) 
showed multiple inflections, for example, at the second 
and fifth PCs, the first three components were retained 
as these reflected all included metabolites. The items that 
cluster on the same components suggest PC1, PC2 and 
PC3 represent the metabolites reflective of the acylcar-
nitine, amino acid and sphingolipid metabolism, respec-
tively (online supplementary material S6). These three 
components could explain 43.7% of the variance in the 
data.
association between acylcarnitines, amino acids and 
sphingolipids with incident T2d
During a median follow- up of 3 years (IQR 2; 4), 22 
participants of Dutch and 73 participants of South- Asian 
Surinamese ethnicity developed T2D. Characteristics and 
metabolite concentrations of participants who developed 
T2D in comparison to the randomly selected subcohort 
are shown in the online supplementary materials S7 and 
S8.
PC1, reflective of the acylcarnitine metabolism, was 
positively associated with incident T2D (HR: 1.10 (95% 
CI 1.02 to 1.19) per 1 SD; figure 3). Because of negative 
factor loadings on PC1, this means that higher levels of 
acylcarnitines were associated with a lower risk of T2D. 
Factor loadings on PC2 (amino acids) and PC3 (sphin-
golipids) were positive, and these components were 
positively associated with T2D (HR: 1.42 (95% CI 1.24 
to 1.62) and 1.11 (95% CI 1.01 to 1.23) per 1 SD, respec-
tively). Thus, indicating that higher concentrations of 
amino acids and sphingolipids were associated with inci-
dent T2D. There was no evidence for multiplicative inter-
actions by ethnicity (online supplementary material S9).
In line, higher concentrations of most individual acyl-
carnitines decreased the risk for T2D (figure 3). C5:0, 
C14:2 and C18:2- carnitine were, however, associated with 
a higher risk for T2D (eg, C18:2 HR 1.30 (95% CI 1.01 
 o
n
 M
ay 11, 2020 at BVA. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-001003 on 5 May 2020. Downloaded from 
7BMJ Open Diab Res Care 2020;8:e001003. doi:10.1136/bmjdrc-2019-001003
Epidemiology/Health Services Research
to 1.68) per 1 SD). Most individual amino acids, on the 
other hand, were positively associated with incident T2D 
(eg, isoleucine HR 3.11 (95% CI 2.22 to 4.35) per 1 SD), 
but in particular glycine and glutamine were negatively 
associated with incident T2D. Individual sphingolipids 
showed contrasting results. Higher levels of (dihydro)
ceramides d17:1, d18:1, d20:1 and d18:0 increased the 
risk for T2D (eg, Cer d18:1 HR 2.38 (95% CI 1.81 to 3.12) 
per 1 SD), while lactosylceramides d18:2 and d18:1, on 
the other hand, reduced T2D risk (eg, HR 0.57 (95% CI 
0.42 to 0.78) per 1 SD for lactosylceramide 18:1). CTH 
d18:1 and d18:2 were non- significantly associated with 
reduced T2D risk (HR 0.77 and 0.78 (95% CI 0.58 to 1.01 
and 0.60 to 1.03)).
ConCLusIons
Our study suggests that, in general, most plasma concen-
trations of acylcarnitines are comparable between Dutch 
and South- Asian Surinamese, while concentrations of 
amino acids were higher and concentrations of sphingo-
lipids were lower among South- Asian Surinamese than 
the Dutch. Associations between metabolites and inci-
dent T2D were similar in South- Asian Surinamese and 
the Dutch. Higher levels of most circulating amino acids 
and (dihydro)ceramides were associated with higher risk 
for T2D, while higher levels of glycine, glutamine, lacto-
sylceramides and most acylcarnitines were associated 
with lower T2D risk. Taken together, this suggests that 
the mechanisms underlying ethnic differences in amino 
acid and lactosylceramide concentrations could be inves-
tigated further to identify whether the mechanisms 
contribute to or predict the higher T2D risk among 
South- Asian Surinamese compared with Dutch.
acylcarnitines
Contrary to our expectations, we demonstrated a small, 
but negative association of acylcarnitines with inci-
dent T2D in both a set of highly correlated metabolites 
(PC1) and for individual acylcarnitines. Cross- sectional 
studies lead to the expectation that acylcarnitines inflict 
insulin resistance and T2D,23–25 though cross- sectional 
studies among European, Korean and Chinese popula-
tions suggested a lack in association.26–28 Evidence from 
prospective studies is limited but suggested positive asso-
ciations between acylcarnitines and T2D.7 10 Perhaps we 
might have been unable to detect associations between 
acylcarnitines and incident T2D due to the low plasma 
concentrations of acylcarnitines limiting contrasts. 
Combining the results of these studies, it remains unclear 
whether elevated levels of acylcarnitines inflict insulin 
resistance and thereby T2D, or are a consequence of 
T2D.29
amino acids
The observed strengths and directions of associations are 
in line with previous studies on prevalent and incident 
T2D among various populations,5 10 30–32 and South Asians 
in particular.5 10 Importantly, we showed that BCAA and 
aromatic amino acids were associated with T2D risk, and 
other amino acids as well. Several mechanisms involving 
amino acids, and more specifically BCAAs (leucine, isole-
ucine and valine), have been hypothesized to cause insulin 
resistance and T2D. These include impaired function of 
branched- chain amino acid aminotransferase (BCAT) 
and branched- chain α-keto acid dehydrogenase (BCKDH) 
due to either genetic abnormalities or elevated fatty acids, 
proinflammatory cytokines or insulin levels leading to the 
accumulation of BCAAs, and also activation of the mTOR/
S6K1 kinase pathway, which contributes to insulin resis-
tance.33 For some amino acids, we showed an opposite 
association. For instance, glycine and glutamine were nega-
tively associated with incident T2D, which is consistent with 
other studies.26 32 34 This may reflect increased gluconeo-
genesis,26 which is also observed in T2D cases.35 Interest-
ingly, we did not observe the associations to differ between 
ethnic groups, as was suggested in previous studies. Tillin 
et al report glycine to be negatively associated with T2D in 
Europeans but not in South Asians (interaction p=0.05).5 
We also did not find evidence for the reported stronger 
adverse association with T2D for tyrosine, alanine and 
phenylalanine in South Asians than in Europeans.5 We, 
therefore, propose that amino acid alterations are equally 
detrimental across ethnic groups.
Due to the higher plasma concentrations of most amino 
acids, and lower concentrations of glycine among South- 
Asian Surinamese, amino acids may, to some extent, 
contribute to the higher risk for T2D among South- Asian 
Surinamese. Our study adds to these previous findings 
that BCAAs,5 and a wide range of amino acids and specif-
ically those related to reduced liver function (methi-
onine, alanine, phenylalanine, tyrosine and lysine),11 may 
contribute to the higher risk for T2D among South- Asian 
Surinamese compared with Dutch. If confirmed, liver func-
tion may, therefore, be a factor to be targeted to prevent 
the high risk for T2D among South- Asian Surinamese.
sphingolipids
Our study confirmed that (dihydro)ceramides increase 
T2D risk.36 37 Several mechanisms, including β-cell apop-
tosis and pancreatic inflammation, were proposed to be 
involved in the risk posed by high levels of ceramides.38 
However, in contrast to studies suggesting associations 
between deoxysphingolipids and T2D, we did not find a 
significant association between Cer m18:0 (also referred 
to as deoxydihydroceramide).39 This may be related to 
differences in analytical techniques. Importantly, we 
suggest that lactosylceramides are associated with a 
decreased T2D risk. This has not been described before, 
though glucosylceramides and lactosylceramides have 
been associated with lower fasting plasma insulin levels.9 
Future studies are needed for confirmation and to inves-
tigate mechanisms behind this protective effect. One 
could speculate that bound ceramides, such as lactosylce-
ramides, could not exert their detrimental effects. On the 
other hand, levels of enzymes involved in production of 
 o
n
 M
ay 11, 2020 at BVA. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-001003 on 5 May 2020. Downloaded from 
8 BMJ Open Diab Res Care 2020;8:e001003. doi:10.1136/bmjdrc-2019-001003
Epidemiology/Health Services Research
more complex sphingolipids could be decreased in those 
at risk for T2D, as was shown in genetically obese mice.40
Concentrations of most sphingolipids were lower 
among South- Asian Surinamese than Dutch, which is in 
line with a small- scale study by van Valkengoed et al with a 
limited set of sphingolipids.10 The lower plasma concen-
trations among South- Asian Surinamese than Dutch 
imply that non- oxidative pathways may not contribute 
to the high risk for T2D among South- Asian Surinamese 
compared with Dutch. Since palmitoyl- CoA is one of the 
rate- limiting substrates for de novo synthesis of sphingo-
lipids,37 this may be related to lower intakes of saturated 
fatty acids among South- Asian Surinamese compared with 
Dutch,41 but may also have other causes, for example, 
ethnic differences in reflection of sphingolipid concen-
trations from individual organ compartments in plasma.
Our study is not exempt from limitations. First, although 
data were prospectively obtained, we cannot exclude reverse 
causation. Moreover, due to the short follow- up period 
we were unable to conduct landmark analyses to exclude 
the cases of diabetes diagnosed during the first years of 
follow- up. The observed associations between metabolites 
and incident T2D may either signify metabolic disturbances 
leading to T2D or reflect metabolic disturbances caused by 
an earlier stage of T2D. Second, incident T2D was deter-
mined from insurance data. Therefore, only those partic-
ipants who received diabetes care were registered as T2D 
cases. We will have missed participants who despite having 
developed T2D were not diagnosed with T2D, for instance, 
because they did not visit their general practitioner during 
the period of follow- up or due to registration issues. Results 
should therefore be interpreted with care, especially since 
screening rates for T2D between ethnic groups may differ 
due to differences in awareness of T2D risk across ethnic 
groups. Awareness rates were previously shown to be 
higher among ethnic minority populations compared with 
the Dutch.42 Moreover, we used probabilistic data linkage 
to link to the Vektis database, so not all participants might 
be linked to the correct corresponding record. This may 
have led to uncertainties in T2D status. Given the more 
than 98% overlap of T2D statuses of participants identified 
in both the Achmea and the Vektis databases, however, we 
believe that the data linkage was of sufficient quality.
Altogether, our study suggests that dysregulation of 
metabolic profiles precedes incident T2D in both Dutch 
and South- Asian Surinamese. Increased concentrations 
of certain acylcarnitines, glycine, glutamine and lactosyl-
ceramides are associated with decreased T2D risk, while 
higher plasma concentrations of (dihydro)ceramides and 
most amino acids are associated with increased T2D risk. 
Although confirmation is needed in future studies, we 
suggest that disruptions of the long- chain fatty acid metab-
olism and increased use of non- oxidative pathways do not 
contribute to the higher T2D risk among South- Asian Suri-
namese compared with Dutch, while disturbed liver amino 
acid metabolism may potentially contribute. Overall, these 
data suggest that the disturbances underlying amino acid 
and sphingolipid metabolism may be predictive of T2D risk 
in populations of both South Asian and European back-
ground. Future studies may use our observations as starting 
point to unravel the underlying metabolic disturbances.
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